Skip to Content


Government-Owned Inventions; Availability for Licensing

Document Details

Information about this document as published in the Federal Register.

Document Statistics
Document page views are updated periodically throughout the day and are cumulative counts for this document including its time on Public Inspection. Counts are subject to sampling, reprocessing and revision (up or down) throughout the day.
Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble


National Institutes of Health, HHS.




The invention listed below is owned by an agency of the U.S. Government and available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

Start Further Info


Chris Kornak at 240-627-3705 or Start Printed Page 20645 Licensing information and copies of the U.S. patent application listed below may be obtained by communicating with the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301-496-2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished information related to the invention.

End Further Info End Preamble Start Supplemental Information


Technology description follows:

Continuous Cell Lines Persistently Expressing High Levels of Native HIV-1 Envelope Trimers on Their Surface Membrane

Description of Technology: Transduced human cell lines expressing high levels of native HIV-1 Envelope on their surface membrane, in the unmodified or interdomain stabilized form. These cell lines provide a stable source of native HIV-1 envelope for multiple uses, including the high-efficiency production of virus-like particles (VLPs) for use as vaccines, testing new inhibitors or neutralizing antibodies, or identifying/capturing B cells that produce broadly neutralizing antibodies from infected/vaccinated humans or animals.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration.

Potential Commercial Applications:

  • High-efficiency production of virus-like particles (VLPs).
  • A means to test new inhibitors or neutralizing antibodies targeting HIV-1 envelope trimers.
  • Probe for identifying/capturing B cells that produce broadly neutralizing antibodies.

Competitive Advantages:

  • The interdomain-stabilized form does not bind CD4 and is locked in the native prefusion form.

Development Stage:

  • Research Use.

Inventors: Paolo Lusso (NIAID), Peng Zhang (NIAID).

Publications: Zhang, Peng, et al. “Interdomain stabilization impairs CD4 binding and improves immunogenicity of the HIV-1 envelope trimer.” Cell host & microbe 23.6 (2018): 832-844.

Licensing Contact: To license this technology please reference E-185-2018-0, and contact Chris Kornak at 240-627-3705 or

Collaborative Research Opportunity: The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology. For collaboration opportunities, please contact Chris Kornak at 240-627-3705 or

Start Signature

Dated: April 30, 2019.

Suzanne M. Frisbie,

Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases.

End Signature End Supplemental Information

[FR Doc. 2019-09618 Filed 5-9-19; 8:45 am]